Skip to main content
Clinical Trials/NCT02120014
NCT02120014
Completed
Not Applicable

A Prospective Study to Determine the Association of Quantitated Blood and Plasma (Intravascular) Volume to Right Heart Hemodynamics, Venous Capacitance, and Regulatory Neurohormones in Patients With Chronic Heart Failure of Reduced and Preserved Ejection Fraction

Mayo Clinic1 site in 1 country60 target enrollmentApril 21, 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congestive Heart Failure
Sponsor
Mayo Clinic
Enrollment
60
Locations
1
Primary Endpoint
Total Blood Volume Measurement
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The primary hypothesis is that patients with HFREF (heart failure with reduced ejection fraction) will demonstrate a markedly expanded intravascular volume which will correlate with elevated right heart hemodynamics and increased venous capacitance parameters, whereas patients with HFPEF(heart failure with preserved ejection fraction) will demonstrate euvolemia to mild volume expansion and a lack of correlation with hemodynamic and venous compliance parameters.

Detailed Description

The purpose of this study is to learn more about how the heart, blood vessels and blood volume interact in patients with heart failure and how measuring blood volume and vein capacity may help us develop better ways of treating and managing heart failure patients. This study will use two tests to measure blood volume and test the capacity of your veins and arteries in your limbs. The blood volume test (also called a plasma volume test or a red cell mass test) is a standard clinical nuclear lab procedure used to measure the volume (amount) of blood in the body. The test also measures the volume of plasma and of red cells in the blood. The other test is called a venous plethysmography, which is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Venous plethysmography measures the changes in the dimensions of your limbs by the use of strain gauges placed on the skin.

Registry
clinicaltrials.gov
Start Date
April 21, 2014
End Date
July 6, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Wayne L. Miller, M.D., Ph.D.

Professor of Medicine

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • age \>18 years
  • patients identified with heart failure and diagnosed clinically to require right heart hemodynamic evaluation, New York Heart Association functional Class II-IV status/Stage C-D heart failure
  • ischemic or nonischemic etiology heart failure
  • left ventricular ejection fraction measured within 6 months of study enrollment

Exclusion Criteria

  • known significant intrinsic chronic kidney disease (baseline Glomerular Filtration Rate \<15 ml/min/1.73m²) or patients receiving hemodialysis
  • known renal artery stenotic disease
  • females who are pregnant
  • allergy to iodine contrast, intravenous pyelogram dye, shellfish or eggs.

Outcomes

Primary Outcomes

Total Blood Volume Measurement

Time Frame: Baseline prior to a clinically indicated right heart catheterization.

Blood volume will be measured at baseline for eligible patients prior to a clinical right heart catheterization.

Secondary Outcomes

  • venous plethysmography(Baseline prior to a clinically indicated right heart catheterization.)

Study Sites (1)

Loading locations...

Similar Trials